PeptiSystems has secured a significant growth equity investment from Rubicon Healthcare Partners, marking a pivotal step in the company’s plan to expand its commercial presence and scale its advanced manufacturing technologies for peptide and oligonucleotide therapeutics. The investment positions Rubicon as the largest shareholder in the Uppsala-based life science company. It provides new capital to accelerate both international expansion and the development of next-generation manufacturing solutions for a rapidly growing biopharmaceutical market.
PeptiSystems, known for its technology platform supporting the production of therapeutic peptides and oligonucleotides, is preparing for larger industrial applications as demand increases for scalable and GMP-compatible manufacturing systems. The new capital will strengthen the company’s commercial development efforts, support organizational expansion, and help advance customer transitions toward industrial-scale and GMP manufacturing.
Rubicon Healthcare Partners specializes in growth investments in Nordic life science companies operating across healthcare and biopharmaceutical supply chains. Its involvement brings industry experience, global networks, and strategic support that will be central to PeptiSystems’ next phase of growth.
The transaction is subject to standard closing conditions, including review under Sweden’s Foreign Direct Investment legislation.
KEY QUOTES:
“We are pleased to welcome Rubicon Healthcare Partners as a new shareholder in PeptiSystems. Their global life science experience and Nordic presence will be a valuable asset as we take the next steps in driving commercialization and scale our technology for industrial applications. This investment reflects confidence in our team and our strategy to drive growth in a rapidly expanding market.”
Karin Granath, CEO, PeptiSystems
“We are proud to partner with PeptiSystems and support their robust growth strategy. The company’s strong values, commitment to excellence, and strategic vision align nicely with our investment philosophy. We were attracted to PeptiSystems’ innovative best-in-class instrument portfolio, customer-centric approach, and excellent management team.”
Ole J. Dahlberg, Managing Partner, Rubicon Healthcare Partners
“I welcome Rubicon as major shareholder in PeptiSystems. This financial injection will further speed up our growth ability in providing our unique flow through technology for the production of therapeutic peptides and oligos.”
Mats Johnson, Chairman of the Board, PeptiSystems
